Articles · HRT

HRT and Cardiovascular Risk Timing

The heart case for HRT depends on when you start, not just whether.

6 min read · Published May 30, 2026 · Updated August 28, 2026

Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.

HRT and Cardiovascular Risk Timing

Heart disease is the leading cause of death in postmenopausal women. The menopausal transition is itself a heart risk event, separate from ageing. Losing estrogen reduces the function of the blood vessel lining, shifts cholesterol the wrong way, stiffens the arteries, and adds visceral fat and insulin resistance. Estrogen’s protective effect on the heart in the premenopausal years is one reason women’s heart disease rates historically ran about a decade behind men’s.

The research history here is one of the clearest examples of a study being misread at population scale.

What the WHI Actually Showed

The Women’s Health Initiative (WHI) trial found that combined estrogen plus progestogen did not reduce coronary heart disease events, and in the first year appeared to raise them. This drove a widespread reading, passed to the public and many doctors, that HRT was bad for the heart.

The key problem was the average age of the participants: 63, with most women more than 10 years past their final period.[1] The trial was not studying what happens when you start HRT near menopause. It was studying what happens when you add estrogen to blood vessels that had already spent a decade building up plaque without estrogen support.

When the WHI data were reanalysed by age group, a different picture appeared. Women who started HRT in their 50s, within 10 years of menopause, had fewer coronary heart disease events than placebo. Women who started 20 years after menopause had more.[1] Timing was everything.

The Timing Hypothesis

The timing hypothesis holds that estrogen protects healthy blood vessels, where its anti-inflammatory, antioxidant, and lining-supporting effects can work, but that in vessels already diseased, estrogen may make plaque less stable and raise the near-term risk of a heart event.[2]

Estrogen supports the vessel lining in several ways: it boosts nitric oxide (which keeps vessels open and blood pressure in check), reduces LDL oxidation, improves HDL cholesterol, and lowers inflammation in the vessel wall.[3] These effects need an intact lining. Once significant plaque has built up, the same mechanisms may work differently or cause harm.

Starting HRT near menopause, before the vessels have aged, keeps both the heart benefit of estrogen and the healthy vessel environment it needs. Starting many years later may miss that window.

The ELITE Trial

The first large randomised trial built specifically to test the timing hypothesis was published in 2016 by the ELITE Research Group.[4] ELITE enrolled 643 healthy postmenopausal women with no clinical heart disease and assigned them to oral estradiol plus vaginal progesterone or placebo. Women were grouped by time since menopause: under six years (early) or over ten years (late).

In the early group, women on estradiol had slower progression of atherosclerosis (measured by carotid intima-media thickness, a validated marker of early heart disease) than placebo. In the late group, there was no meaningful difference between estradiol and placebo.

ELITE gave the first direct experimental evidence that the heart benefit of HRT depends on timing rather than being absent. It also confirmed that starting HRT late does not give the same benefit.

What This Means in Practice

Taken together, the evidence points to a clear through-line: timing and route are the two factors that most determine heart benefit or risk, and both are decided at the point of prescribing.

Starting HRT early keeps options open. Women who start near the onset of perimenopause are in the window where a heart benefit is most plausible. The case for HRT is strongest before the vessels have aged.

HRT near menopause is not a heart treatment on its own. The evidence supports it as protective in healthy women during the transition, not as a therapy for women with established heart disease or for late-onset HRT use.

Route matters. The higher clot and stroke risk with oral HRT is part of the heart risk picture. Transdermal estradiol does not carry the same clot risk as oral estrogen and is preferred for women with heart risk factors, per current guidelines.[5]

The protective window may close. NAMS, NICE, and the British Menopause Society agree: for healthy women under 60, or within 10 years of menopause, the heart benefit-and-risk balance favours HRT for symptomatic women. For women starting more than 10 years after menopause, or over 60 with no established reason, the heart benefit is less certain.

Hot Flashes as a Vascular Signal

The heart effects of the transition reach well beyond the years around menopause. In observational studies, postmenopausal women who had significant hot flashes during the transition had roughly double the rate of heart events in later decades compared with women who had few.[3] Severe hot flashes may be a marker of underlying vascular vulnerability.

So treating hot flashes promptly during the transition may carry a long-term heart benefit, not just a quality-of-life benefit. Whether treating hot flashes directly lowers later heart risk, or whether they are only a marker rather than a cause, is an active research question. But the signal is consistent enough that the frequency and severity of hot flashes are increasingly part of heart risk discussions alongside the traditional factors.

When to Talk to Your Doctor About Heart Risk

Not every woman starting HRT needs a cardiology referral, but a heart-focused conversation with your prescriber is warranted before starting if you have any of the following: a personal or strong family history of heart attack or stroke before age 60, a history of blood clots (deep vein thrombosis or pulmonary embolism), poorly controlled high blood pressure, type 2 diabetes with vascular complications, or you are more than 10 years past your final period. In these situations, route (transdermal versus oral), type of progestogen, and a baseline heart risk assessment all become active decisions rather than defaults, and the conversation is worth having before starting, not after.


References

[1] Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended post-stopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353-1368. See also: The timing hypothesis. https://pubmed.ncbi.nlm.nih.gov/27085786/

[2] Clarkson, T. B., Meléndez, G. C., Appt, S. E. (2013). Timing hypothesis for postmenopausal hormone therapy: Its origin, current status, and future. Menopause, 20(3), 342-353. See also: Cardiovascular health and the menopausal woman. https://pmc.ncbi.nlm.nih.gov/articles/PMC6733383/

[3] Thurston, R. C., Chang, Y., Barinas-Mitchell, E., et al. (2017). Menopausal hot flashes and subclinical cardiovascular disease. Menopause, 24(5), 489-495. See also: Clinical impact of estrogen loss on CVD in menopausal females. https://pmc.ncbi.nlm.nih.gov/articles/PMC7059770/

[4] Hodis, H. N., Mack, W. J., Henderson, V. W., et al. (2016). Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine, 374(13), 1221-1231. https://doi.org/10.1056/NEJMoa1505241

[5] The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The Menopause Society. Menopause, 29(7), 767-794. https://doi.org/10.1097/GME.0000000000002028

Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.